The Flupentixol/Melitracen combination is used for symptomatic support in mild to moderate emotional disorders where symptoms are mixed and may include a lack of energy. The therapeutic support is applied in contexts marked by both emotional and physical manifestations.

Relief for Mixed Anxiety and Low Mood

This medication is commonly used to help with symptom clusters that include anxiety, depression, and asthenia, providing a supportive role in emotional management. As a combination used for mental disorders including anxiety and depression, the drug is relevant for easing symptoms that interfere with daily comfort. It provides supportive relief for these manifestations, which may help reduce the overall burden of symptoms that interfere with daily functioning.

Addressing Fatigue, Apathy, and Listlessness

The approach is relevant for easing symptoms related to asthenia and lack of energy, often associated with a focus on countering fatigue. This is applied when symptoms create noticeable functional strain and interfere with daily functioning.

Managing Stress-Related Somatic Symptoms

Stimo is commonly used in clinical settings where symptoms related to emotional distress and anxiety are linked to or exacerbate physical (somatic) complaints. This is applied in addressing supportive relief for symptoms in functional disorders like Psychosomatic Affections accompanied by anxiety and apathy, and may assist with easing symptoms that interfere with daily comfort.

Quick Fact: Relief for Mixed Symptoms

The therapeutic approach supports patients experiencing low mood and anxiety that are simultaneously complicated by fatigue and reduced drive.

Who Can and Cannot Use Stimo?

This section describes the officially documented population eligibility and non-eligibility criteria for Stimo, strictly based on regulatory labeling.

Absolute Contraindications

Use of this medicine is strictly prohibited for patients with known hypersensitivity to the active ingredients (flupentixol or melitracen) or related compounds. Absolute prohibitions include recent myocardial infarction, any degree of atrioventricular block or severe cardiac conduction disorders, and conditions resulting in circulatory collapse or acute CNS depression (e.g., from alcohol or opiates). The medicine must not be used by patients currently receiving or having recently received Monoamine Oxidase Inhibitors (MAOIs). Further contraindications include untreated narrow-angle glaucoma and phaeochromocytoma.

Age and Conditional Restrictions

The product is generally restricted to use in adults (18 years and older) and is not recommended for children and adolescents due to insufficient data on safety and efficacy. Caution is required in the older adult population, and for those with pre-existing conditions such as advanced hepatic disease, renal impairment, a history of convulsions, or hyperthyroidism. Regarding pregnancy, use should preferably not be given, and it is not recommended during lactation, as stated in the official regulatory documents.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for the Flupentixol/Melitracen combination, as outlined in government regulatory labeling.

Contraindicated Combinations and Timing

The combination of Stimo with Monoamine Oxidase Inhibitors (MAOIs) is absolutely prohibited due to the risk of Serotonin Syndrome. A mandatory 14-day separation period must be observed when discontinuing non-selective MAOIs before starting this medicine, or vice versa. For selective MAO-A or MAO-B inhibitors (such as moclobemide or selegiline), a minimum one-day separation is required.

Pharmacodynamic Potentiation

Co-administration with other substances that act on the central nervous system may lead to enhanced effects. This includes CNS Depressants (such as barbiturates, general anesthetics, or opiates), where the risk of CNS depression is increased. The Melitracen component may also potentiate the cardiovascular effects of Sympathomimetic Agents (e.g., adrenaline) and the side effects of Anticholinergic Agents (e.g., Atropine). Use with drugs that cause QT prolongation or affect cardiac rhythm is generally restricted. The neuroleptic component reduces the antihypertensive effect of drugs like Guanethidine.

Exposure and Bleeding Risk

Interactions may modify drug levels or increase specific risks. For instance, Amobarbital is documented to increase the metabolism of Melitracen. Co-administration with Anticoagulants or drugs affecting coagulation, such as NSAIDs or Aspirin, may potentiate anticoagulant effects and increase the risk of gastrointestinal bleeding. Alcohol consumption should be avoided as it enhances the sedative response.

Stimo is an agonist that interacts selectively with the P2 Y12 receptor, which is a Gi-protein coupled receptor ( GPCR) found on the surface of platelets. The binding of Stimo to the P2 Y12 receptor initiates a signal that results in the inhibition of adenylyl cyclase (AC).

Inhibition of AC subsequently leads to a reduction in the cellular concentration of the second messenger, cyclic AMP ( cAMP), within the platelet. This decrease in cAMP modulates downstream intracellular signaling pathways, including the activation status of GP IIb/ IIIa receptors. The overall result is a defined, molecular modulation of platelet function by directly affecting these intracellular processes.

How Stimo is Used

Stimo, the fixed-dose combination product containing 0.5 mg of Flupentixol and 10 mg of Melitracen, is intended for oral administration as a film-coated tablet. Its usage is strictly guided by the prescribing information. The tablets are swallowed whole with water and can generally be taken with or without food.

---

Standard Adult Regimens

The standard procedure for initiation and typical use involves a divided daily dose. The usual recommended adult regimen is one tablet in the morning and one tablet at noon, resulting in a typical total daily dose of two tablets. This timing is confined to the daytime (morning and noon) as part of the official labeled administration pattern. In clinical scenarios considered more severe, the daily dosage may be increased, where the morning dose is raised to two tablets. The official label specifies a definitive maximum daily dose of four tablets (corresponding to 2 mg Flupentixol and 40 mg Melitracen).

---

Population-Specific Use and Duration

Administration rules are adjusted for specific populations. For older adults (over 65 years), treatment initiation typically begins at a lower dose of one tablet, once daily in the morning. The use of Stimo is not recommended for children and adolescents due to a lack of established clinical data. A distinct element of the administration protocol involves a time-based assessment: if a satisfactory result is not achieved within one week while taking the maximum dosage, the medication should be withdrawn, providing a clear endpoint for trial duration as defined in the official prescribing documents.

Research Evidence / Overview of Studies for Stimo

Evidence from Trials for Mixed Anxiety and Low Mood

Research has explored the Flupentixol/Melitracen combination in adults with mild to moderate emotional conditions characterized by mixed anxiety and low mood, often alongside fatigue or a lack of energy. Researchers primarily used short-term Randomized Controlled Trials (RCTs) and meta-analyses in evidence describing how symptoms are measured. These studies monitored changes in symptom intensity using standardized tools, such as the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale (HAMD). Studies report how symptoms evolved in the observed populations during the defined study intervals, which typically lasted for a few weeks.

However, certainty remains low for some findings. Many of the trials summarized in the scientific literature are older, and some may have methodological limitations in their reporting. Additionally, the follow-up durations were limited. Research provides insight into short-term changes, but there is limited information for long-term outcomes or how symptoms might evolve after the initial weeks of study observation.

---

Studies on Somatic Symptoms and Functional Disorders

Research also explored the combination in studies related to conditions where emotional distress was associated with physical discomfort or functional imbalance. Research specifically examined symptom patterns in settings like functional dyspepsia and certain forms of Irritable Bowel Syndrome (IBS). These investigations included specific Randomized Controlled Trials and broader systematic reviews applied in research contexts involving fluctuating or unstable symptoms. These studies monitored outcomes related to physical discomfort and patient-reported outcomes describing perceived discomfort.

Evidence quality varies across studies, with some analyses citing a medium risk of bias in the pooled data. Furthermore, some research was conducted within specific regional populations, meaning results apply only to the populations studied and may limit generalizability. Data for conditions like persistent pain primarily come from observational settings, meaning the certainty remains low compared to formal controlled trials.

---

Duration of Study Follow-up and Key Evidence Gaps

Research exploring short-term symptom changes monitored responses over defined time intervals, typically between 2 and 8 weeks in the main clinical trials. The scientific literature indicates that long-term effects are not fully established for this combination. There are few data available that address the persistence of measured changes over extended periods.

Key areas of scientific uncertainty include limited long-term data and insufficient data for certain groups, such as older adults or those with complex comorbidity profiles.

Key Studies & References

1. Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial
2. Deanxit film-coated tablets - Summary of Product Characteristics (SPC)

Common questions about Stimo (FAQ)

Q: How quickly should I expect to feel the effects of Stimo?

Clinical studies and official information suggest that some patients may notice initial effects relatively quickly. However, if a satisfactory result is not achieved after approximately one week on the maximum dosage, it is typically recommended that the medication be re-evaluated for withdrawal.

Q: What's the typical duration of Stimo's effects after one dose?

While the exact length of the therapeutic effect for a single dose is not typically detailed in patient information, one of the active ingredients, Flupentixol, has an elimination half-life of approximately 35 hours. The drug's administration schedule is designed to support consistent effects.

Q: Does Stimo interact with common over-the-counter pain relievers?

Official information states that Stimo may interact with certain non-prescription pain relievers, specifically Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Aspirin. Combining these with Stimo may enhance blood-thinning effects. It is essential that a healthcare provider is aware of all over-the-counter medications being used.

Q: Can Stimo cause changes in sleep patterns?

Yes, official product information lists insomnia (difficulty sleeping) as a common side effect of the combination product. Other effects like restlessness and sedation (sleepiness) may also occur, indicating that the medicine can alter normal sleep patterns.

Q: Are there any specific foods or drinks to avoid while taking Stimo?

Official product information cautions against the consumption of alcohol during treatment. This is because Stimo can enhance the sedative effects of alcohol, potentially leading to increased drowsiness. There are no specific restrictions noted for food while taking the medicine.

Q: What happens if I miss a dose of Stimo?

If a dose is missed, regulatory documents recommend taking the dose as soon as it is remembered. However, if it is nearly time for your next scheduled dose, it is typically recommended that the missed dose be skipped. Product instructions warn against taking a double dose to make up for a missed tablet.

Q: Is it normal to feel [mild, common side effect] when first starting Stimo?

It is not uncommon to experience some of the common side effects, such as headache, dizziness, restlessness, or insomnia, when first starting Stimo. These effects are sometimes observed early in treatment and may lessen over time as the body adjusts.

Q: Does Stimo affect blood pressure or heart rate?

Yes, official product warnings indicate that Stimo can affect the cardiovascular system. The medicine is contraindicated (should not be used) in patients with severe cardiac conduction issues. A drop in blood pressure when standing, known as orthostatic hypotension, is a documented side effect.

Q: Does Stimo have a risk of dependence or withdrawal symptoms?

Regulatory documents advise against stopping the medicine suddenly, particularly after using high doses or for long periods, as abrupt cessation may lead to withdrawal symptoms. All decisions regarding stopping the medication should be made in consultation with a healthcare professional.

Q: Is there any research that shows how effective Stimo is compared to placebo?

Studies summarized in regulatory documents confirm that Stimo's effectiveness for symptoms of anxiety and depression is supported by evidence from clinical trials and meta-analyses. These trials evaluate its performance against control groups, including placebo, using established symptom rating scales.

Q: Is Stimo safe for women who are planning to become pregnant?

According to official regulatory documentation, the medicine should preferably not be administered during pregnancy unless a doctor deems it clearly necessary. If taken late in pregnancy, there is a potential for neonatal withdrawal symptoms. Consultation with a healthcare provider is recommended for women who are planning a pregnancy.

Q: Can Stimo cause mood changes or emotional side effects?

Although Stimo is intended to treat low mood and anxiety, official product information indicates that side effects like restlessness, agitation, and rarely hypomania (abnormally elevated mood) may occur. Regulatory warnings also note the potential risk of suicidal ideation, especially at the start of treatment or after dose adjustments.

Q: What is the mechanism of action of Stimo?

Stimo is a fixed combination of two active ingredients. Melitracen acts as a tricyclic antidepressant by supporting levels of mood-regulating chemicals like norepinephrine and serotonin. Flupentixol, at the low dose used here, is utilized for its activating and anti-anxiety properties. The combination is intended to provide both antidepressant action and activating properties.

Q: Can Stimo be crushed, split, or chewed, or must it be swallowed whole?

Official patient instructions state that Stimo is provided as a film-coated tablet and must be swallowed whole with water. The tablets should not be crushed, split, or chewed, as they are designed to be absorbed when swallowed intact.

Q: Does Stimo interact with anti-depressants or anxiety medications?

Yes, Stimo has serious interaction risks with other psychiatric medicines. It is absolutely contraindicated (prohibited) with all Monoamine Oxidase Inhibitors (MAOIs). It can also enhance the sedative effects of many other central nervous system depressants, requiring cautious use alongside other anti-depressants or anti-anxiety drugs.

Q: Can Stimo be taken with other maintenance medications for chronic conditions?

Official documentation advises caution, as Stimo may interact with various maintenance medications, including those for blood pressure (antihypertensives) and blood clotting (anticoagulants). Due to the complexity of these interactions, it is crucial that all chronic medications are reviewed by the prescribing healthcare provider.

Q: Are there different strengths or formulations of Stimo available?

The official product information specifies that this fixed-dose combination is manufactured as film-coated tablets containing 0.5 mg of Flupentixol and 10 mg of Melitracen. This is the only strength and formulation of this specific combination widely available.

Q: What is the average shelf life of Stimo pills?

Regulatory information typically states the shelf life for Stimo film-coated tablets is 3 years from the date of manufacture. This duration applies when the medication has been stored correctly according to the temperature and protection requirements specified on the packaging.

How to Store and Dispose of Stimo?

The storage and disposal of Stimo (Flupentixol/Melitracen oral tablets) must adhere strictly to official regulatory requirements to maintain product integrity and ensure safety.

Storage Requirements

Requirement	Condition
Temperature	Store below 25 C and do not freeze.
Protection	Protect from light and humidity; keep in the original blister pack and outer carton.
Safety	The medicine must be stored out of the sight and reach of children.

---

Disposal Instructions

Unused or expired Stimo must be disposed of in accordance with local requirements for pharmaceutical waste. It is mandatory not to throw away medicines via wastewater or household waste to prevent environmental contamination.